Highlights Edwards Lifesciences Corporation

Equities

EW

US28176E1082

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 05:00:02 17/01/2026 HKT			5-day change	1st Jan Change
84.35 ^USD	-0.17%		-0.27%	-1.06%

01-13	Edwards Lifesciences Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 11:15 AM
01-12	UBS Adjusts Price Target on Edwards Lifesciences to $95 From $92, Maintains Neutral Rating	MT

Highlights

01-12	Independence, Under Review
01-12	Edwards Lifesciences Drops Bid to Acquire JenaValve Technology	MT
01-10	Edwards Lifesciences Drops Merger With JenaValve	DJ
01-10	Edwards says co will not acquire Jenavalve	RE
01-10	US FTC wins ruling blocking Edwards Lifesciences' acquisition of JenaValve	RE
12-23	FDA approves Edwards Lifesciences' Sapien M3 mitral valve replacement system as first transseptal transcatheter therapy	RE
12-23	FDA Approves Edwards Lifesciences' Sapien M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy	CI
12-19	North American Morning Briefing : Stock Futures Up as Investors Bet on Fed Rate Cuts -2-	DJ
12-18	Inflation Took a Chill Pill
12-06	Sector Update: Health Care Stocks Lower Late Afternoon	MT
12-04	Edwards Lifesciences Reiterates 2025 Guidance; 2026 Forecast Issued	MT
12-04	Edwards Lifesciences reaffirms strategy for sustainable, differentiated growth at annual investor conference	RE
11-18	Medtronic raises annual sales growth forecast on heart devices demand	RE
11-17	Royal Philips Introduces DeviceGuide	CI
11-11	Edwards Lifesciences Insider Sold Shares Worth $1,080,093, According to a Recent SEC Filing	MT
11-06	The Market Can't Make Up Its Mind
11-06	Tranche Update on Edwards Lifesciences Corporation (NYSE:EW)'s Equity Buyback Plan announced on July 28, 2022.	CI
11-03	The Church of Artificial Optimism
31/10/25	Edwards Lifesciences beats quarterly estimates on strength in heart devices	RE
31/10/25	Edwards Lifesciences Q3 Adjusted Earnings Flat, Revenue Rises; Q4 Guidance Set	MT
31/10/25	Edwards Lifesciences CFO Scott Ullem to step down by mid-2026	RE
31/10/25	(EW) Edwards Lifesciences Corporation Expects Q4 Revenue Range $1.51B - $1.59B	MT
31/10/25	(EW) Edwards Lifesciences Corporation Expects Q4 Adjusted EPS Range $0.58 - $0.64	MT
31/10/25	Earnings Flash (EW) Edwards Lifesciences Corporation Reports Q3 Revenue $1.55B, vs. FactSet Est of $1.50B	MT
31/10/25	Earnings Flash (EW) Edwards Lifesciences Corporation Posts Q3 Adjusted EPS $0.67 per Share, vs. FactSet Est of $0.60	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Edwards Lifesciences Corporation: The story continues

April 23, 2024 at 11:25 pm